Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2013 1
2014 1
2015 2
2016 2
2017 3
2018 5
2019 3
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean poitou c[au] (154 results)?
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors.
O'Hara MH, Messersmith W, Kindler H, Zhang W, Pitou C, Szpurka AM, Wang D, Peng SB, Vangerow B, Khan AA, Koneru M, Wang-Gillam A. O'Hara MH, et al. Among authors: pitou c. J Pancreat Cancer. 2020 Mar 12;6(1):21-31. doi: 10.1089/pancan.2019.0018. eCollection 2020. J Pancreat Cancer. 2020. PMID: 32219196 Free PMC article.
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, Hamilton A, Fiorica J, Moore KN, Teneriello M, Golden L, Zhang W, Pitou C, Bell R, Campbell R, Farrington DL, Bell-McGuinn K, Wenham RM. Vergote I, et al. Among authors: pitou c. Gynecol Oncol. 2020 Jan;156(1):23-31. doi: 10.1016/j.ygyno.2019.11.006. Epub 2019 Nov 29. Gynecol Oncol. 2020. PMID: 31791552 Clinical Trial.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, Hynes S, Pitou C, Campbell R, Iversen P, Farrington DL, Bell-McGuinn K, Thomas M. Bendell JC, et al. Among authors: pitou c. Invest New Drugs. 2020 Aug;38(4):1145-1155. doi: 10.1007/s10637-019-00873-6. Epub 2019 Nov 9. Invest New Drugs. 2020. PMID: 31707688
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A. Goldman JW, et al. Among authors: pitou c. Invest New Drugs. 2018 Aug;36(4):629-637. doi: 10.1007/s10637-017-0532-2. Epub 2017 Dec 1. Invest New Drugs. 2018. PMID: 29196957 Free PMC article. Clinical Trial.
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.
Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C, Shen W, Strelow JM, Halstead C, Rempala ME, Parthasarathy S, Gillig JR, Heinz LJ, Pei H, Wang Y, Stancato LF, Dowless MS, Iversen PW, Burkholder TP. Ma L, et al. Among authors: pitou c. Blood Cancer J. 2013 Apr 12;3(4):e109. doi: 10.1038/bcj.2013.6. Blood Cancer J. 2013. PMID: 23584399 Free PMC article.
16 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page